A common and often debilitating condition, affecting women of reproductive age.
Abnormal uterine bleeding (AUB) is any variance of the normal menstrual cycle, which is defined on the basis of four parameters (frequency, regularity, duration, and volume).
The International Federation of Gynecology and Obstetrics PALM-COEIN classification system improves the understanding of the causes of AUB, facilitates effective history taking and examination, and allows for shared decision-making towards tailored investigations and management plans.
A range of medical and surgical management options are available, and the choice of treatment is guided by the underlying cause of AUB alongside the patient's age, parity, co-morbidities, need for uterine and fertility preservation, and personal preference.
Abnormal uterine bleeding (AUB) is the term used to describe any symptomatic variation from normal menstruation in terms of regularity, frequency, volume, or duration. It also includes inter-menstrual bleeding (IMB). This differs from dysfunctional uterine bleeding (DUB), which is diagnosed by excluding pregnancy, iatrogenic causes, systemic conditions, and genital tract pathology.
History and exam
Professor of Obstetrics and Gynaecology
Centre for Women's and Newborn Health
Institute of Metabolism and Systems Research
University of Birmingham
Birmingham Women’s and Children’s Hospital
JG is an advisory member for Femcare Nikomed UK for the Filshie clip. He has received an HTA grant for the ECLIPSE trial; a randomised controlled trial comparing the Mirena coil with oral medical treatments for heavy menstrual bleeding. He has received travel costs for training workshops for Dilapan-S osmotic dilators for abortion and the induction of labour (Medicem).
Senior Clinical Fellow
Department of Reproductive Medicine
St. Mary’s Hospital
AS declares that she has no competing interests.
Clinical Research Fellow
MRC Centre for Reproductive Health
The Queen's Medical Research Institute
University of Edinburgh
RC is supported as a Clinical Research Fellow by Bayer AG; RC declares that he has no other competing interests.
Professor Gupta, Dr Sood, and Dr Chodankar would like to gratefully acknowledge Dr Mohamed Mitwally and Dr Intisar Elnahhas, the previous contributors to this topic. MM owns a patent on the use of aromatase inhibitors for endometrial thinning before hysteroscopic surgery. The patent is licensed to Meditrina Company. IE declares that she has no competing interests.
Department of Family and Community Medicine
Southern Illinois University School of Medicine
JA is an author of a reference cited in this topic.
Associate Professor (CHS)
Department of Family Medicine
University of Wisconsin
SS declares that she has no competing interests.
Use of this content is subject to our disclaimer